Market Place
Sourcing Support
All News #Library
Biotech
Armata Pharma Reveals 2025 Financial Performance
25 Mar 2026 //
PR NEWSWIRE
Armata Pharma Delays Q4, FY 2025 Results; Issues Update
19 Mar 2026 //
PR NEWSWIRE
Armata Pharma Advances AP-SA02 to Phase 3 for S. aureus
13 Jan 2026 //
PR NEWSWIRE
Armata Pharma Hosts KOL Webinar On S. Aureus Bacteremia & AP-SA02
18 Nov 2025 //
PR NEWSWIRE
Armata Pharma Reveals Q3 2025 Results & Corporate Update
12 Nov 2025 //
PR NEWSWIRE
Armata Pharma Commissions cGMP Phage Facility In Los Angeles
10 Nov 2025 //
PR NEWSWIRE
Armata Pharma Showcases AP-SA02, Phase 2A Results At Idweek 2025
22 Oct 2025 //
PR NEWSWIRE
Armata Pharma To Unveil Clinical Data On AP-SA02, At IDweek 2025
14 Oct 2025 //
PR NEWSWIRE
Armata Pharma Reveals Structural Biology Publication in Journal
08 Sep 2025 //
PR NEWSWIRE
Armata Shares Positive Data from diSArm SA Study
19 May 2025 //
PR NEWSWIRE
Armata Pharmaceuticals Announces Q1 2025 Results and Update
14 May 2025 //
PR NEWSWIRE
Armata Pharmaceuticals gets $4.65M from U.S. DoD for AP-SA02 trial
01 May 2025 //
PR NEWSWIRE
Armata Pharma Reports Results from AP-PA02 Phase 2 Study
19 Dec 2024 //
PR NEWSWIRE
Armata Pharma CEO Dr. Deborah Birx to Present at Phage Futures
19 Nov 2024 //
PR NEWSWIRE
Armata Pharma Announces Q3 2024 Results & Update
13 Nov 2024 //
PR NEWSWIRE
Armata Pharma Completes Enrollment for AP-SA02 Bacteremia Study
12 Nov 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Announces Structural Biology Publication
30 Oct 2024 //
PR NEWSWIRE
Armata Pharmaceuticals Joins H.C. Wainwright Global Investment Conference
05 Sep 2024 //
PR NEWSWIRE
Armata Announces First Patient Dosed in Phase 2a of Study of AP-SA02
26 Sep 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.